All In Biotech

Drug Trial Radar · NCT00265811

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,559 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,559

Actual

Start

Nov 2005

Primary completion

Nov 2009

Study completion Jun 22, 2010

Sponsor

Lead sponsor
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, or fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy with or without cetuximab after surgery may kill any remaining tumor cells and keep colon cancer from coming back. It is not yet known whether giving combination chemotherapy together with cetuximab is more effective than giving combination chemotherapy alone in treating colon cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy and cetuximab to see how well they work compared to combination chemotherapy alone in treating patients with stage III colon cancer that was completely removed by surgery.

Conditions

  • Colorectal Cancer

Interventions

  • FolfoxDrug

  • CetuximabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survivalTime frame: 3-years DFS

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Hopital Duffaut

    Avignon, France

  • CHU de Caen

    Caen, France

  • Hopital Robert Boulin

    Libourne, France

  • Hopital Bichat - Claude Bernard

    Paris, France

  • CHU Pitie-Salpetriere

    Paris, France

  • Hopital Tenon

    Paris, France

  • Centre Hospitalier Yves Le Foll

    Saint-Brieuc, France

  • Nouvelle Clinique Generale

    Valence, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.